Graphene stocks
Archer Materials Limited (ASX: AXE) announced on June 6, 2026, a significant technical breakthrough in the integration of its 12C biochip technology with graphene field--effect transistors (gFETs). The company successfully demonstrated sub--nanomolar detection limits for viral pathogens, a critical milestone for the commercialization of its point--of--care diagnostic platform. This validation of foundry--compatible fabrication processes is expected to facilitate high--volume manufacturing and accelerate strategic partnerships with global medical device and pharmaceutical companies.